lunes, 10 de marzo de 2014
domingo, 9 de marzo de 2014
Polypharmacy is a problem, although sometimes a necessary evil.
Is this my real life?
Is this my destiny?
I've been caught in a landslide,
Must escape polypharmacy.
I've opened my eyes,
Looked up to the skies now I see,
If I'm not a sick boy, I need no remedy,
But I trusted you, you should know
You started high, never low,
Many guidelines are opinions so they may not apply to me, to me.
Medications, can kill a man,
Like a gun against his head,
Used too many, now he's dead.
Medications, can also help,
So no don't go and throw them all away.
I'll give them a try,
But if I've not improved at all by this time tomorrow,
I won't carry on, carry on unless I'm feeling better.
Too late, this drug I'm on,
Made mincemeat of my mind,
Body's aching all the time.
Come on some drugs have got to go,
Gotta leave these all behind and find what works. (Más)
Do take the time to watch this fantastivideo by James McCormack.
Gracias al "pitazo" de Antonio Villafaina
sábado, 8 de marzo de 2014
busca aplicar estrategias empresariales
a la creación de recursos
para los más necesitados".
Nan Wise es una terapeuta sexual y candidata al doctorado en neurociencia cognitiva en la Universidad de Rutgers. Es una mujer de 56 años con un gran sentido del humor que ha decidido tomar en sus manos la difícil tarea de investigar la joya de la corona de la corteza somatosensorial del cerebro humano: el orgasmo femenino.
Su (heroico) trabajo de doctorado busca comprender las implicaciones clínicas en el tratamiento de dolores pélvicos en mujeres al igual que en disfunciones sexuales femeninas como la anorgasmia (ausencia de orgasmos) y los dolores en la penetración (dispareunia), además del bajo deseo sexual y otros padecimientos que afectan tanto a hombres como mujeres.
Para Wise, a pesar del enorme avance hecho en el siglo xx para hacer un esquema funcional de la anatomía interna del clítoris (que incluye trabajos como el de una de sus colaboradoras más notables, la doctora Beverly Whipple, responsable de dar nombre al famoso punto G), la corteza somatosensorial es en realidad un misterio por descubrir; un continente oculto cuyo mapa puede encontrarse en las placas de resonancia magnética (fMRI) tomadas a numerosos sujetos de prueba (incluyéndola a ella misma) mientras se estimulan hasta alcanzar el orgasmo.
Wise se ha masturbado en el interior de los incómodos tubos de resonancia más veces que ninguna otra persona en el planeta, y ha tenido orgasmos a través de estimulación directa del clítoris, orgasmos a través de estimulación de las paredes vaginales, de estimulación cervical e incluso orgasmos inducidos exclusivamente a través del pensamiento. De esta curiosa habilidad, Wise escribe: ”Podía llevarme al orgasmo con el pensamiento sin ninguna estimulación física incluso antes de comenzar a estudiar el sexo. Atribuyo esta habilidad a los muchos años de intenso estudio de yoga.” (...)
¿Estarías dispuesta a donar tus orgasmos en favor de la ciencia, aunque implicara masturbarte con un dildo sin poder abrir demasiado las piernas mientras estás dentro de un estrecho tubo que hace un ruido ensordecedor a tu alrededor? Si lo estás, probablemente compartas el espíritu científico y la vocación por comprender el mecanismo del placer de la doctora Wise y sus colegas.(Más)
|Jane Fonda experiences Death-by-Orgasm in the film Barbarella|
A day in the life of a sex researcher
viernes, 7 de marzo de 2014
Boston public library
Un correo de Mike Wokasch me advierte sobre este libro:
"Thank you for the blog post highlighting Pharmaplasia. You might find it interesting that Pharmaplasia is referenced in the the just published book "The Antidote:Inside the world of New Pharma" written by Barry Werth the author of The Billion Dollar Molecule."
El comentario es ya una garantia de calidad...
"The hero of "The Antidote," in any case, is not a charismatic individual but a company. It's a book about a particular organization's attempt to sustain innovation in rapidly changing commercial and biomedical circumstances."
Steven Shapin, professor of the history of science at Harvard University.
Journalist and author Barry Werth has been writing about the business and practice of the pharmaceutical industry for more than two decades. The Billion Dollar Molecule, his 1995 book on Vertex Pharmaceuticals, was named one the “75 Smartest Books We Know” by Fortune. His sixth and most recent book, The Antidote: Inside the World of Big Pharma, revisits Vertex, offering unprecedented behind-the-scenes access to a company that that went from cash-starved startup to a triumph of American bio-tech innovation. Werth has also written for The New Yorker, The New York Times, and Technology Review, among many others publications.
In THE ANTIDOTE, Barry Werth draws upon unprecedented inside reporting spanning more than two decades to provide a groundbreaking closeup of the upstart pharmaceutical company Vertex and the ferocious but indispensable world of Big Pharma that it inhabits.
"Antes de morir trató de decir algo, acaso un nombre, una fecha. Trató de besarla, ella volvió la cabeza y empezó a hablar rápidamente de Jim, del "Gragón Rojo". Faltaba poco tiempo para que se despidieran.
Al fin llegó la ambulancia, inútil. Era preciso decirle algo, tratar de arreglarlo como fuera. No le contestó nadie aquella noche, en el lago. Nunca llovería sobre Kentucky. Subieron el cadaver lentamente a la ambulancia, como si estuviera a punto de decirle algo. Antes de que se marchara, de que abandonara la ciudad para siempre."
"Vivo dentro de la fantasía paranoica del fin del mundo y no sólo quiero salir de ella sino que pretendo que los demás entren en ella.
Todas mis palabras son la misma que se inclina hacia muchos lados, la palabra FIN, la palabra que es el silencio, dicha de muchos modos. Porque es un FIN que incluye a todos en la única tragedia a la que solo se puede contemplar participando en ella. Es la tragedia convertida en absoluto y por consiguiente desaparecida.
Es la muerte que desaparece."
Poética (De Hortus conclusus)Fallece Leopoldo María Panero, el poeta de Nunca Jamás
jueves, 6 de marzo de 2014
Leonard Schleifer, the founder and chief executive of the biotechnology company Regeneron, is now a billionaire according to Forbes’ estimates. He joins only a small number of pharmaceutical industry executives to reach that level of wealth.
Regeneron, based in Tarrytown, N.Y., has seen its share price increase 220% over the past two years as its drug Eylea, a treatment for age-related macular degeneration, has reached $1.9 billion in annual sales and new experimental medicines for high cholesterol, rheumatoid arthritis, and asthma near that market as part of a deal with drug giant Sanofi.
Regeneron had annual sales of $2.1 billion, a 53% increase from the year before, and the company sports a market capitalization of $33.7 billion. (...)
It was the mid-1980s. He began to see a lot of papers coming from Genentech, one of the first biotechnology companies. “What is a company doing all this great scientific stuff?” he asked himself. “I realized they were not only publishing stuff, they were doing the most modern science and it was really very impressive.” But no biotechnology company, he realized, was doing similar work on diseases of the nervous system.
Gilman tried to talk Schleifer out of going into business, telling him he had a great career ahead of him in medicine. But Schleifer wouldn’t be dissuaded. He managed to hook up with George Sing, a venture capitalist at Merrill Lynch, at a Chinese restaurant and walked out with $1 million in funding. Knowing that his own skills at the lab bench would not be enough, he recruited a 28-year-old scientist, George Yancopoulos, to be his co-founder. They have turned into one of biotech’s most enduring teams. (Más)
"Extraña persecución a la marca en una economía de libre mercado y en un país que saca pecho internacionalmente con su propia marca."
Extraña persecución a las marcas farmacéuticas en una economía de libre mercado
(*)Licenciado en Farmacia y doctor por la Universidad de Valladolid. Diplomado en Salud Pública. Experto en iniciativas estratégicas en salud. Colaborador de MUNDIARIO.
miércoles, 5 de marzo de 2014
Swiss pharma group Novartis will work more closely with rival Roche but rules out a merger, its chairman said in a newspaper interview on Sunday.
Asked whether the two companies wanted to stay independent, Joerg Reinhardt, who took over as Novartis chairman in August, told Swiss newspaper SonntagsZeitung: "Absolutely."
He said, however, that he'd met outgoing Roche Chairman Franz Humer a few weeks ago and was also exchanging emails with his successor Christoph Franz.
"Two pharma groups working in the same location have many topics in common," he said. Both Roche and Novartis are based in Basel in north-western Switzerland.
Asked whether Novartis could sell its stake in Roche that was built up under his predecessor Daniel Vasella, Reinhardt said: "The shares are in good hands with us. For as long as Roche does well, we take pleasure in them."
Novartis holds a third of Roche's bearer shares.
In October, Roche Chief Executive Severin Schwan also knocked back speculation that the company could merge with Novartis.
Reinhardt said in the interview Novartis hoped to conclude an ongoing review of its over-the-counter drugs, animal health and vaccines businesses by the end of the year.
"Then we will know if and how we have to change our structure and organisation," he said, adding discussions on possible buys or divestments were under way with partners.
"There are not many players and everybody talks to everybody," he said.
Novartis said in January it was looking at options for the three businesses and wanted the review to be completed by the end of summer.
Reinhardt said Novartis' profitability was only temporarily under pressure due to quality issues in the U.S. and Canada, the fact that the vaccines division was not profitable and falling sales of its former blockbuster Diovan.
"Our profitability will rise again," he said, without giving details. (Más)
Avanafilo es de VIVUS...
martes, 4 de marzo de 2014
Today in Basel, Novartis shareholders ratified Joerg Reinhardt's move into the chairman's seat.
That might be considered the final, official farewell in former Chairman Daniel Vasella's long goodbye.
But shareholders also approved other, more nitty-gritty changes in corporate governance that explicitly undo some of Vasella's work.
It's as if the company has shut the door behind Vasella and called in house cleaners to dust away his fingerprints. "It strikes me as a deliberate attempt to officially call the end of the Vasella era at Novartis," Florian Wettstein, director of the Institute for Business Ethics at Switzerland's University of St. Gallen, told The Wall Street Journal.
If you've been following Novartis news lately, you know those nitty-gritty changes--the disbanding of two board committees that kept Vasella in the loop on M&A deals and executive pay, among other things--are just a small part of the ongoing overhaul there. The Swiss drugmaker sold off its blood diagnostics business, announced a strategic review of its other smaller businesses, and continued a global cost-cutting effort with layoffs, facility closures and consolidations, and more.
|Novartis human resources building|
by Frank Gehry
Y en el recientemente celebrado "Investor Day" Joe habló y dijo:
So let me start by talking about the strategy and I want to start by talking a little bit about where we have come from as a company. So back when Novartis was formed in 1996 with the combination of Ciba-Geigy and Sandoz, we were less than 50% healthcare and over the next 17 years obviously we managed the portfolio to be focused 100% on healthcare. And you can see here some of the acquisitions and the divestitures that occurred over the years and shaped the company. The most significant was Alcon done in 2010. Now we have completed the Alcon acquisition and we’re moving into the next growth phase of the company. Those shareholders that have stuck with the Company have been well rewarded so our total shareholders return since creation of Novartis has exceeded that of our peers and the world pharma market.
Now, we’re now moving into a new phase of the Company and we’re sharpening the execution of our strategy and we’re strengthening the portfolio. So what does that look like? I want to reinforce the strategy of the company and that has not changed. Our strategy is to win through science based innovation that’s focused on high growth segments of healthcare.
Since I’ve become CEO, I have focused the company on
three strategic priorities;
- the first is, extending our leading innovation, which to me means, making sure that our pipelines are best in class in every segment that we compete in;
- the second is accelerating growth, which means turning that innovation into sales and profit growth that hits the P&L; and
- then finally driving productivity. I talk about productivity as being strategic at Novartis given that it allows us to reinvest and to also show profit improvement.
Now let me touch on innovation. For over 10 years, we have been refining our approach to discovery and starts with the pathways approach continually focusing on future technologies as well as creating a unique culture in our research organization that leads to significant innovation. Now the pathways approach that we talk about involves studying molecular signaling networks within cells that are responsible for normal cell function. Now we know that there is only a handful of pathways that we know of and they’re shared across diseases. (Más)
Todo Vasella en PHARMACOSERÍAS
Glaxo CEO’s Bonus Reduced by China Bribery Investigation
Chief Executive Officer Andrew Witty received a bonus less than the maximum possible because of a Chinese investigation into bribery allegations against the company.
Witty’s bonus of 1.88 million pounds ($3.13 million) was lower than the potential 2.12 million pounds he might have gotten, Glaxo said today in its annual report. Even so, the bonus was more than double the amount awarded for 2012 after the company won regulatory approval of six products last year.
China began an anti-corruption probe focused on London-based Glaxo in July. Allegations by China’s government that Glaxo bribed hospitals, doctors and officials contributed to a plunge in revenue from that country and a hit to its corporate image.
GSK & China en PHARMACOSERÍAS